TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02942576
Drug: VKA-Based Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed at INR levels. Standard of Care treatment in Spain.
Study: NCT04508621
Drug: Placebo SL Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
Study: NCT00057785
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
Study: NCT02336698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Study: NCT01725737
Drug: GlyTI-M
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01725737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: starch
Study: NCT00377715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03137758
Drug: PCUR - 101
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
Study: NCT02432456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
Study: NCT02432456
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
Study: NCT02432456
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate \> 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
Study: NCT02432456
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.
Study: NCT01552629
Drug: QGE031
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01552629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00763971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once per day (Overencapsulated)
Study: NCT03809455
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge...), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day
Study: NCT03809455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one intake of placebo (intranasal or buccal)
Study: NCT00388505
Drug: Tobramycin Inhalation Powder
Normalized name: Tobramycin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin Inhalation Powder (TIP) capsules for inhalation.
Study: NCT00388505
Drug: Tobramycin Solution for Inhalation
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
Study: NCT02173301
Drug: XP23829 400 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: active dose 1
Study: NCT02173301
Drug: XP23829 400 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: active dose 3
Study: NCT02173301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control
Study: NCT00430638
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
Study: NCT00430638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered for once daily for 12 weeks
Study: NCT01083758
Drug: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical suspension applied once daily for up to 8 weeks
Study: NCT00618436
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
Study: NCT00719550
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at 625mg/m2 BID orally every day while on study.
Study: NCT01017575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, daily, 48 weeks
Study: NCT01007253
Drug: PL nasal spray
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
Study: NCT01007253
Drug: PL eye drops
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
Study: NCT02517099
Drug: Beclometasone
Normalized name: Beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclometasone dipropionate 200mcg bd for 4 months
Study: NCT02517099
Drug: Co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 0.3ml/kg bd for 4 weeks
Study: NCT04388475
Drug: OKN-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.
Study: NCT02048293
Drug: Remifentanyl, Ultiva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic induction for orotracheal intubation. Group O
Study: NCT02048293
Drug: Remifentanil Laboratorios Chalver de Colombia S.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic induction for orotracheal intubation. Group A
Study: NCT02048293
Drug: Fada Remifentanilo
Normalized name: Remifentanilo
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic induction for orotracheal intubation. Group B
Study: NCT02793128
Drug: UGN-101 instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
Study: NCT02517099
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 10mg/kg od for 4 weeks
Study: NCT00062036
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06537778
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
Study: NCT01529749
Drug: EFV/FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/200/245 mg, od, oral
Study: NCT01529749
Drug: FTC/TDF + MK-0518
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral
Study: NCT03995628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of placebo on post-operative day 3 after tonsillectomy
Study: NCT03496805
Drug: MGE
Normalized name: Emgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will take 4 capsules by mouth BID (twice daily).
Study: NCT04515576
Drug: LY3493269
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04515576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01074047
Drug: Conventional Care Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician pre-selects prior to randomization from one of the following:~* Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~* Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~* Best Supportive Care only; until study end
Study: NCT01876810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One lactose pill twice a day for two weeks.
Study: NCT02461030
Drug: In-office Villevie® prophy paste + Colgate Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
Study: NCT04637620
Drug: Placebo Cap
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo as a comparator
Study: NCT02182245
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01480284
Drug: GSK548470 300 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
Study: NCT01480284
Drug: ETV 0.5 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
Study: NCT01681134
Drug: Advagraf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01681134
Drug: Prograf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04439071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01415882
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03555448
Drug: Twice daily immunosuppression regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
Study: NCT04036448
Drug: REVLIMID®
Approvals — FDA: no, EMA: no, PMDA: no
Description: REVLIMID®
Study: NCT00623974
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 milligrams by mouth (PO) Every 12 Hours
Study: NCT01647750
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
Study: NCT01647750
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in the standard dose of treatment will receive their usual dose of levothyroxine
Study: NCT01389024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
Study: NCT03302299
Drug: Pyridoxine 25 Mg Oral Tablet
Normalized name: pyridoxine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
Study: NCT00850837
Drug: HEC gel
Normalized name: ALCOHOL 73 L in 100 L TOPICAL GEL [Grand Valley Reagents HEC Hand Sanitizer Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g application of hydroxyethylcellulose gel
Study: NCT02827123
Drug: Macintosh Laryngoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
Study: NCT01679366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet 2 times daily
Study: NCT01679366
Drug: Probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet twice daily
Study: NCT03250975
Drug: Budesonide and Azithromycin
Normalized name: formoterol and budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
Study: NCT01245595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT01494662
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
Study: NCT02787369
Drug: ACY-1215
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00504907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00049452
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01817855
Drug: AZD7624
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
Study: NCT01817855
Drug: Placebo to match
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses inhaled placebo via a nebulizer
Study: NCT02657356
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02610153
Drug: Vitamin K Antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
Study: NCT05079789
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with amiloride, start dose 5 mg
Study: NCT00782795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00807963
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human hyaluronidase PH20 injection
Study: NCT00807963
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injection
Study: NCT00335894
Drug: hMG-IBSA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00068588
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03415126
Drug: ASN007 RD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral drug for the treatment of advanced solid tumors
Study: NCT03829241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to troriluzole
Study: NCT00698204
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject was asked to take celecoxib each day that radiation therapy was given.
Study: NCT00698204
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject was asked to take placebo each day that radiation therapy was given.
Study: NCT02209454
Drug: Enantyum® oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of 25 mg DKP oral solution
Study: NCT01945554
Drug: Mephamesone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01945554
Drug: Kenacort®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01292447
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert gel x 1
Study: NCT04480424
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT per local policies or guidelines.
Study: NCT04218084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT02805582
Drug: 10ml ropivacain 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided nerve block
Study: NCT00536809
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given BID days 1-14
Study: NCT03249181
Drug: Standard of Care (EFV + 2 NRTI backbone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
Study: NCT03646240
Drug: ABI-009
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
Study: NCT04382755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
Study: NCT00799175
Drug: ropivacaine, ketorolac and epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
Study: NCT00657904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00396032
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
Study: NCT02836743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03396926
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally (PO)
Study: NCT03603509
Drug: Fluad Vaccine
Normalized name: Fluad 2024-2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
Study: NCT04612309
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient treated with at least 1 immunotherapy administration
Study: NCT02675426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; Oral
Study: NCT00637052
Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Study: NCT01001715
Drug: Placebo (for REGN475/SAR164877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes
Study: NCT03582007
Drug: One anti-pseudomonal antibiotic
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either meropenem or piperacillin-tazobactam
Study: NCT04622488
Drug: Diclofenac Potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: - In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
Study: NCT01752712
Drug: CBSST + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
Study: NCT04958512
Drug: Yangxue Qingnao pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
Study: NCT02969733
Drug: isotonic saline serum intravenous administration
Approvals — FDA: no, EMA: no, PMDA: no